6 results about "Surface Glycoproteins" patented technology

Described are structural identifications of the F and G proteins of a large variety Henipaviruses and their use in creating immunogens useful for vaccine compositions, and in prevention and treatment of Paramyxovirus and Henipavirus infections in a mammal. Also described are methods for screening viral fusion proteins for capability to transition from a pre-fusion to a post-fusion conformation. A monoclonal antibody specific for LayV-F is also provided.

The present invention relates to recombinant Modified Vaccina Virus Ankara (MVA) encoding Epstein-Barr virus (EBV) antigens, wherein surface glycoprotein 350 (EBV gp350) and glycoprotein gH (EBV gH) are fused to subunits of self-assembling multimeric protein particle PdhC (acetyltransferase of pyruvate dehydrogenase (PDH) complex) or DPS (DNA binding protein from starved cells).

Systems and methods are described herein enabling the profiling of local microenvironments across the sialylated proteome via proximity labeling. In one aspect, conjugates are described herein having composition and electronic structure for generating reactive labeling intermediates in microenvironments of sialylated cell-surface glycoproteins. In some embodiments, a conjugate comprises a transition metal catalyst coupled to a cell surface glycoprotein. As described further herein, the transition metal catalyst can be coupled to the glycoprotein via a derivatized sialic acid linker.

This invention discloses a method for diagnosing prostate cancer using exosome surface proteomics, aiming to address the technical problems of insufficient specificity in existing prostate-specific antigen (PSA) detection and the inability of conventional exosome analysis techniques to simultaneously achieve source specificity and proteome coverage. The method includes: collecting and preprocessing biological fluid samples; using a dual-marker orthogonal barcoding system composed of DNA aptamer probes targeting CD63 protein and prostate-specific membrane antigen, respectively, to specifically capture and enrich prostate cancer-derived exosomes; selectively labeling their surface glycoproteins, followed by cleavage and enzymatic digestion to enrich surface glycoprotein peptides; and finally, inputting the data into a diagnostic model trained based on machine learning to output diagnostic results. This invention, through the organic combination of source-specific capture and panoramic surface proteome analysis, significantly improves the specificity and sensitivity of diagnosis, providing an efficient solution for non-invasive and accurate diagnosis and invasiveness assessment of prostate cancer.

The invention discloses a multi-epitope peptide of Ebola virus, a vaccine as well as a preparation method and application of the multi-epitope peptide and the vaccine, and belongs to the technical field of biological medicines. The multi-epitope peptide is derived from surface glycoprotein (Glycoprotein, GP) of Zaire type Ebola virus and Sudan type Ebola virus, and the epitope peptide is conserved in the two types of Ebola viruses. In addition, the multi-epitope peptide is both a T cell epitope and a B cell epitope. An epitope peptide and a nano delivery carrier are connected through a linker to prepare a vaccine, the vaccine comprises the multi-epitope peptide or a combination thereof, a free KFE8 self-assembly peptide and a PADRE-KFE8 fusion peptide, and a nano fiber structure is formed through self-assembly of the multi-epitope peptide or the combination thereof, the free KFE8 self-assembly peptide and the PADRE-KFE8 fusion peptide. The preparation method comprises the following steps: dissolving the components in a buffer solution according to a specific molar ratio, and incubating to enable the components to be self-assembled to form nanofibers. The multi-epitope peptide can be used for preparing a vaccine for preventing Ebola virus infection, and the vaccine can induce humoral immunity and cellular immunity at the same time, and has broad-spectrum protection potential for Zaire type and Sudan type Ebola viruses at the same time.

The present disclosure provides compositions and methods for manufacturing and obtaining a live attenuated Influenza vaccine (LAIV) composition that can be delivered intranasally to provide protection against influenza virus infection. Said LAIV strains are based on cold adapted, temperature sensitive and attenuated phenotypes of master donor viruses (MDVs) containing the surface glycoprotein genes of the wild type pandemic or seasonal influenza strains. Also, said LAIV strains are further adapted to grow in MDCK cells (Madin Darby canine kidney cells). The use of eggs is avoided in large scale vaccine manufacturing. The purification process is devoid of chromatography steps. The said LAIV composition includes one or more live attenuated influenza vaccine virus and is devoid of polymers and surfactants.